BBIO

66.39

2.04% 1.33

Handel nachbörslich: 66.60 0.21 +0.32%

Bridgebio Pharma Inc (BBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BBIO? Forum Prognose

Schlusskurs vom Vortag:

$65.06

Offen:

$64

24-Stunden-Volumen:

1.54M

Relative Volume:

0.66

Marktkapitalisierung:

$12.69B

Einnahmen:

$217.77M

Nettoeinkommen (Verlust:

$-438.86M

KGV:

-27.55

EPS:

-2.41

Netto-Cashflow:

$-456.33M

1W Leistung:

+7.43%

1M Leistung:

+17.50%

6M Leistung:

+97.24%

1J Leistung:

+175.36%

1-Tages-Spanne:

$63.91

$67.71

1-Wochen-Bereich:

$62.06

$67.93

52-Wochen-Spanne:

$21.72

$69.48

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Firmenname

Bridgebio Pharma Inc

Sektor

Healthcare (1135)

Branche

Biotechnology (634)

Telefon

(650) 391-9740

Adresse

3160 PORTER DR., PALO ALTO, CA

Mitarbeiter

730

Twitter

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

BBIO's Discussions on Twitter

Vergleichen Sie BBIO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BBIO Bridgebio Pharma Inc	66.39	12.54B	217.77M	-438.86M	-456.33M	-2.41
VRTX Vertex Pharmaceuticals Inc	437.15	110.25B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	693.50	73.04B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	449.16	59.98B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	907.98	54.90B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	193.22	40.73B	447.02M	-1.18B	-906.14M	-6.1812

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-30	Fortgesetzt	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-07-14	Eingeleitet	Jefferies	Buy
2025-07-09	Hochstufung	Oppenheimer	Perform → Outperform
2025-06-17	Eingeleitet	Wolfe Research	Outperform
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-10-03	Eingeleitet	Oppenheimer	Perform
2024-09-04	Eingeleitet	Piper Sandler	Overweight
2024-03-21	Fortgesetzt	Raymond James	Outperform
2024-01-31	Eingeleitet	BMO Capital Markets	Market Perform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-11-07	Eingeleitet	Citigroup	Buy
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-07-18	Herabstufung	Jefferies	Buy → Hold
2023-04-19	Eingeleitet	Evercore ISI	Outperform
2023-02-06	Eingeleitet	Cowen	Outperform
2021-12-27	Bestätigt	Mizuho	Buy
2021-12-27	Bestätigt	SVB Leerink	Outperform
2021-09-10	Hochstufung	BofA Securities	Neutral → Buy
2021-05-21	Eingeleitet	UBS	Buy
2021-03-22	Bestätigt	Goldman	Buy
2021-02-22	Fortgesetzt	JP Morgan	Overweight
2021-02-09	Fortgesetzt	Goldman	Buy
2021-01-11	Bestätigt	H.C. Wainwright	Buy
2020-12-10	Bestätigt	H.C. Wainwright	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Neutral
2020-05-19	Eingeleitet	BTIG Research	Buy
2020-04-13	Eingeleitet	H.C. Wainwright	Buy
2020-02-19	Eingeleitet	Mizuho	Buy
2019-07-26	Eingeleitet	Raymond James	Outperform
2019-07-22	Eingeleitet	BMO Capital Markets	Outperform
2019-07-22	Eingeleitet	Goldman	Buy
2019-07-22	Eingeleitet	JP Morgan	Overweight
2019-07-22	Eingeleitet	Jefferies	Buy
2019-07-22	Eingeleitet	Piper Jaffray	Overweight
2019-07-22	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

12:34 PM

What moving averages say about BridgeBio Pharma Inc.Market Growth Report & Fast Gain Stock Tips - newser.com

12:34 PM

08:42 AM

How dovish Fed policy supports BridgeBio Pharma Inc. (2CL) stock2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com

08:42 AM

04:17 AM

Why BridgeBio Pharma Inc. (2CL) stock stays resilientWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com

04:17 AM

Nov 13, 2025

What drives BridgeBio Pharma Inc stock priceDividend Aristocrats List & Fast Growing Portfolio Trading - earlytimes.in

Nov 13, 2025

Nov 12, 2025

What indicators show strength in BridgeBio Pharma Inc.2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com

Nov 12, 2025

How BridgeBio Pharma Inc. stock performs in stagflationWeekly Risk Report & Consistent Income Trade Recommendations - newser.com

Nov 12, 2025

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Wave Life Sciences (WVE) and BridgeBio Pharma (BBIO) - The Globe and Mail

Nov 12, 2025

BridgeBio Pharma (BBIO): Exploring Valuation After a 20% Share Price Surge - Yahoo Finance

Nov 12, 2025

Nov 11, 2025

Wells Fargo Maintains BridgeBio Pharma (BBIO) Overweight Recommendation - Nasdaq

Nov 11, 2025

BridgeBio Pharma (BBIO): Wells Fargo Raises Price Target to $84 - GuruFocus

Nov 11, 2025

Nov 10, 2025

BridgeBio Pharma CEO Kumar Neil sells $5m in shares By Investing.com - Investing.com Australia

Nov 10, 2025

BridgeBio Pharma CEO Kumar Neil sells $5m in shares - Investing.com

Nov 10, 2025

Bridgebio Pharma Insider Sold Shares Worth $4,983,111, According to a Recent SEC Filing - MarketScreener

Nov 10, 2025

Pfizer’s Advertising Challenge Against BridgeBio’s Attruby Leverages US FDA Untitled Letter - Citeline News & Insights

Nov 10, 2025

Sustained drop in all-cause mortality observed with BridgeBio’s acoramidis - The Pharma Letter

Nov 10, 2025

BridgeBio Pharma Insider Sold Shares Worth $3,888,999, According to a Recent SEC Filing - MarketScreener

Nov 10, 2025

Can machine learning forecast BridgeBio Pharma Inc. recoveryTrade Risk Assessment & Low Risk High Reward Ideas - newser.com

Nov 10, 2025

Nov 09, 2025

Analyzing BridgeBio Pharma Inc. with risk reward ratio chartsTrade Risk Assessment & AI Powered Market Entry Ideas - newser.com

Nov 09, 2025

BridgeBio Pharma’s Global Expansion Shockwave: Why Investors Are Buzzing! - Smartkarma

Nov 09, 2025

BridgeBio (BBIO) Reports Promising Data for Acoramidis in Cardia - GuruFocus

Nov 09, 2025

BridgeBio presents data from ATTRibute-CM study on acoramidis - TipRanks

Nov 09, 2025

Nov 08, 2025

BridgeBio Pharma Reports Significant All-Cause Mortality Reductions with Acoramidis in Variant ATTR-CM Patients at AHA Scientific Sessions 2025 - Quiver Quantitative

Nov 08, 2025

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations - GlobeNewswire

Nov 08, 2025

Using Bollinger Bands to evaluate BridgeBio Pharma Inc.2025 Earnings Surprises & Entry Point Strategy Guides - newser.com

Nov 08, 2025

JP Morgan Raises Price Target for BBIO, Maintains Overweight Rat - GuruFocus

Nov 08, 2025

Nov 07, 2025

BridgeBio Pharma Director Makes a Multi-Million Dollar Stock Move! - TipRanks

Nov 07, 2025

BridgeBio Pharma Director Ronald J Daniels Sells Over $3.8 Million in Company Stock - TradingView

Nov 07, 2025

Long term debt to total equity ratio of BridgeBio Pharma, Inc. – HAM:2CL - TradingView

Nov 07, 2025

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan

Nov 07, 2025

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry - The Manila Times

Nov 07, 2025

Will BridgeBio Pharma Inc. stock pay special dividendsDay Trade & Daily Profit Focused Screening - newser.com

Nov 07, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ceribell, Inc. (CBLL), American Well (AMWL) and BridgeBio Pharma (BBIO) - The Globe and Mail

Nov 06, 2025

How BridgeBio Pharma Inc. (2CL) stock reacts to fiscal policiesWeekly Trend Recap & Reliable Price Breakout Signals - newser.com

Nov 06, 2025

Nov 05, 2025

Why retail investors favor BridgeBio Pharma Inc. stockJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com

Nov 05, 2025

Real time alert setup for BridgeBio Pharma Inc. performance2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com

Nov 05, 2025

Is BridgeBio Pharma Inc. stock a buy in volatile markets2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - fcp.pa.gov.br

Nov 05, 2025